1 / 9

Ledipasvir-Sofosbuvir + RBV in Sofosbuvir-Experienced GT1 HCV Retreatment

This study examines the effectiveness and safety of Ledipasvir-Sofosbuvir + RBV in the retreatment of Sofosbuvir failures with GT1 HCV. Results show high SVR rates and manageable adverse events.

herrerar
Télécharger la présentation

Ledipasvir-Sofosbuvir + RBV in Sofosbuvir-Experienced GT1 HCV Retreatment

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Phase 2 TreatmentExperienced Ledipasvir-Sofosbuvir +RBV in Sofosbuvir-Experienced HCV GT1Retreatment of Sofosbuvir Failures Wyles D, et al. Hepatology. 2015;61:1793-7.

  2. LDV-SOF + RBV in Sofosbuvir-Experienced GT 1 HCVStudy Features Source: Wyles D, et al. Hepatology. 2015;61:1793-7.

  3. LDV-SOF +RBV in Sofosbuvir-Experienced GT 1 HCVStudy Features 0 12 24 Week Ledipasvir-Sofosbuvir + RBV SVR12 N=51 Abbreviations: LDV = ledipasvir; SOF = sofosbuvir; PEG = peginterferon; RBV = ribavirin Drug DosingLedipasvir-sofosbuvir (90/400 mg): fixed-dose combination; one pill once dailyRibavirin (weight-based and divided bid): 1000 mg/day if < 75 kg or 1200 mg/day if ≥ 75 kg Source: Wyles D, et al. Hepatology. 2015;61:1793-7.

  4. LDV-SOF +RBV in Sofosbuvir-Experienced GT 1 HCVBaseline Characteristics Abbreviation: SD, standard deviation Source: Wyles D, et al. Hepatology. 2015;61:1793-7.

  5. LDV-SOF +RBV in Sofosbuvir-Experienced GT 1 HCVBaseline Characteristics Source: Wyles D, et al. Hepatology. 2015;61:1793-7.

  6. LDV-SOF +RBV in Sofosbuvir-Experienced GT 1 HCVStudy Results Virologic Response at Week 4, End-of-Treatment and SVR12, 24 50/51 51/51 50/51 50/51 Abbreviations: LDV= ledipasvir; SOF = sofosbuvir; RBV = ribavirin * The one patient who relapsed found to have genotype 3a infection and was enrolled erroneously. Source: Wyles D, et al. Hepatology. 2015;61:1793-7.

  7. LDV-SOF +RBV in Sofosbuvir-Experienced GT 1 HCVAdverse Events Source: Wyles D, et al. Hepatology. 2015;61:1793-7.

  8. LDV-SOF +RBV in Sofosbuvir-Experienced GT 1 HCVConclusions Source: Wyles D, et al. Hepatology. 2015;61:1793-7.

  9. This slide deck is from the University of Washington’s Hepatitis C Online and Hepatitis Web Study projects. Hepatitis C Onlinewww.hepatitisc.uw.edu Hepatitis Web Studyhttp://depts.washington.edu/hepstudy/ Funded by a grant from the Centers for Disease Control and Prevention.

More Related